Non-Hallucinogenic Psychedelic Analogs for Neural Plasticity

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current antidepressant drugs are ineffective for approximately ⅓ of patients and take 2-4 weeks to show benefits, and classical psychedelics have limited clinical usefulness due to hallucinogenic effects and safety concerns.

Innovation Solution

Development of non-hallucinogenic analogs of psychedelic compounds that increase neural plasticity by promoting dendritic spine growth and synaptic protein synthesis, which can be used to treat brain disorders such as depression, anxiety, and neurodegenerative diseases.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If classical psychedelics are used to treat brain disorders, then neural plasticity is increased, but hallucinogenic effects and safety concerns arise

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidhallucinogenic effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts the beneficial neural plasticity-promoting properties of classical psychedelics while removing the harmful hallucinogenic effects by developing non-hallucinogenic analogs that selectively target plasticity-related pathways

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent modifies chemical parameters of psychedelic compounds to create analogs with altered pharmacological profiles that maintain neuroplasticity effects while eliminating hallucinogenic activity through structural modifications

Inventive Principle:

Principle #35Parameter changes

2Object-affected harmful factors

If traditional antidepressants are used to treat depression, then safety is improved, but treatment duration is extended to 2-4 weeks

Engineering Contradiction:

Improvesafety profileVSAvoidtreatment onset time

Core Design Contradiction:

Object-affected harmful factorsVSLoss of time

Solution Approach 1:

The patent employs compounds that initiate neural plasticity changes more rapidly than traditional antidepressants, effectively performing the therapeutic action in advance of the typical 2-4 week onset period

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent changes the pharmacokinetic and pharmacodynamic parameters of the treatment by using non-hallucinogenic psychedelic analogs that act faster than conventional antidepressants while maintaining an acceptable safety profile

Inventive Principle:

Principle #35Parameter changes

3Object-affected harmful factors

If non-hallucinogenic analogs are developed, then safety is improved by eliminating hallucinogenic effects, but device complexity increases due to compound synthesis

Engineering Contradiction:

Improvehallucinogenic effectsVSAvoidcompound synthesis complexity

Core Design Contradiction:

Object-affected harmful factorsVSDevice complexity

Solution Approach 1:

The patent segments the complex synthesis process into modular steps and identifies key structural features that confer non-hallucinogenic properties, allowing for systematic development of analogs

Inventive Principle:

Principle #1Segmentation

Data Source

PatentUS20250381175A1Compounds for increasing neural plasticity

Publication Date: 2025.12.18 RGT UNIV OF CALIFORNIA

AI summary

The present invention provides a method of using non-hallucinogenic analogs of psychedelic compounds for increasing neural plasticity of the neuronal cell, and a method of using thereof for treating a brain disorder.